A role for inflammatory mediators in heterologous desensitization of CysLT1 receptor in human monocytes.
Cysteinyl-leukotrienes (cysteinyl-LT) are rapidly generated at sites of inflammation and, in addition to their role in asthma, rhinitis, and other immune disorders, are increasingly regarded as significant inflammatory factors in cancer, gastrointestinal, cardiovascular diseases. We recently demonstrated that in monocyte/macrophage-like U937 cells, extracellular nucleotides heterologously desensitize CysLT(1) receptor (CysLT(1)R)-induced Ca(2+) transients. Given that monocytes express a number of other inflammatory and chemoattractant receptors, this study was aimed at characterizing transregulation between these different stimuli. We demonstrate that in U937 cells and in primary human monocytes, a series of inflammatory mediators activating G(i)-coupled receptor (FPR1, BLT(1)) desensitize CysLT(1)R-induced Ca(2+) response unidirectionally through activation of PKC. Conversely, PAF-R, exclusively coupled to G(q), cross-desensitizes CysLT(1)R without the apparent involvement of any kinase. Interestingly, G(s)-coupled receptors (beta(2)AR, H(1/2)R, EP(2/4)R) are also able to desensitize CysLT(1)R response through activation of PKA. Heterologous desensitization seems to affect mostly the G(i)-mediated signaling of the CysLT(1)R. The hierarchy of desensitization among agonists may be important for leukocyte signal processing at the site of inflammation. Considering that monocytes/macrophages are likely to be the major source of cysteinyl-LT in many immunological and inflammatory processes, shedding light on how their receptors are regulated will certainly help to better understand the role of these cells in orchestrating this complex network of integrated signals.
Capra
Valérie
V
Laboratory of Molecular Pharmacology, Università degli Studi di Milano, Milan, Italy.
Accomazzo
Maria Rosa
MR
Gardoni
Fabrizio
F
Barbieri
Silvia
S
Rovati
G Enrico
GE
D002118:Calcium / Q000378:metabolism; D002454:Cell Differentiation / Q000187:drug effects; D002460:Cell Line; D005576:Colforsin / Q000276:immunology; D003888:Desensitization, Immunologic; D004121:Dimethyl Sulfoxide / Q000494:pharmacology; D006801:Humans; D018836:Inflammation Mediators / Q000276:immunology* / Q000378:metabolism; D007545:Isoproterenol / Q000276:immunology; D009000:Monocytes / Q000166:cytology / Q000276:immunology* / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000494:pharmacology; D043562:Receptors, G-Protein-Coupled / Q000276:immunology / Q000378:metabolism; D018077:Receptors, Leukotriene / Q000276:immunology* / Q000378:metabolism; D015290:Second Messenger Systems / Q000187:drug effects / Q000276:immunology
D018836:Inflammation Mediators; D010456:Peptides, Cyclic; D043562:Receptors, G-Protein-Coupled; D018077:Receptors, Leukotriene; C475455:YM-254890; D005576:Colforsin; D009240:N-Formylmethionine Leucyl-Phenylalanine; D007545:Isoproterenol; C083169:leukotriene D4 receptor; D002118:Calcium; D004121:Dimethyl Sulfoxide